Nonhormonal Hot Flash Therapy Meets Phase III Goals

Noven Pharmaceuticals reported positive data from separate 12- and 24-week Phase III trials evaluating low-dose mesylate salt of paroxetine for reducing the frequency and severity of moderate-to-severe vasomotor symptoms associated with the menopause.
Genetic Engineering & Biotechnology News